Resources Blog Custom Antibody Development: A Step-by-Step Guide

Custom Antibody Development: A Step-by-Step Guide

Biointron 2024-03-13 Read time: 10 mins
Image credit: DOI: 10.3389/fonc.2021.672262

Antibodies are indispensable tools in both research and clinical diagnostics, serving as highly specific detectors of antigens - molecules capable of eliciting an immune response. Custom antibody development refers to the generation of antibodies against a specific antigen of interest, which may not be available on a catalog. This approach allows researchers to study novel proteins, post-translational modifications, or unique molecules with precision and specificity. The importance of custom antibodies extends beyond basic research, playing crucial roles in therapeutic interventions, vaccine development, and diagnostic assays.

This guide navigates through the necessary steps involved in development, including antigen design, immunization, hybridoma generation or recombinant display technologies, antibody production, purification, characterization, and, finally, applications and future perspectives. Understanding each phase is essential for the successful development of antibodies that meet specific research or clinical needs. 

A. Antigen Design

The first step in custom antibody development is the selection and design of the target antigen. Antigens are usually proteins or peptides that evoke an immune response, leading to antibody production. The selection criteria include the antigen's immunogenicity, the epitope's accessibility, conservation across species, and the antigen's relevance to the study's objectives. 

Antigen design often involves bioinformatics tools to identify epitopes - the specific parts of the antigen recognized by antibodies. These tools, like homology modeling, analyze protein structures and sequences to pinpoint epitopes - the exact regions on the target antigen that antibodies can bind to. This allows researchers to identify the most promising areas for antibody development, even if the complete 3D structure of the target protein is unknown.  

To produce the designed antigen, techniques such as peptide synthesis offer a rapid and versatile method for creating short amino acid chains that mimic specific epitopes. This is useful for initial testing but may not fully capture the antigen's natural 3D shape, which can be crucial for optimal antibody binding. For more complex and realistic antigens, recombinant protein expression is employed. Here, the gene encoding the desired antigen or specific epitopes is introduced into a host cell. The host cell machinery then produces the protein, allowing for larger and structurally accurate antigens. These methodologies allow for incorporation of modifications to enhance immunogenicity or mimic post-translational modifications. 

The presentation of the antigen to the immune system significantly affects the outcome of the immunization. This can involve conjugation to carrier proteins, encapsulation in nanoparticles, or incorporation into adjuvants to enhance immunogenicity. The choice of presentation method depends on the nature of the antigen and the desired type of immune response.  

B. Immunization

The choice of animal species for immunization is guided by several factors, including the phylogenetic distance to humans (for generating antibodies that cross-react with human proteins), the animal's size, and ethical considerations. While mice are readily available and well-studied, their distant evolutionary relationship to humans can sometimes lead to antibodies that don't work well on human proteins. Large-scale production favors bigger animals like goats or sheep that can generate more antibodies. Rabbits offer a strong antibody response, but their antibodies can trigger unwanted immune reactions in humans. Ultimately, researchers consider all these factors, along with ethical concerns about animal welfare, to choose the most suitable species for developing antibodies. 

Effective immunization protocols are tailored to induce a robust and sustained immune response. This involves multiple injections of the antigen, spaced over weeks or months, with careful monitoring of the animal's immune response through serum testing. Enzyme-linked immunosorbent assays (ELISAs) are a common serological assay used to measure the titer of antigen-specific antibodies in the blood. This monitoring allows researchers to assess the effectiveness of the immunization regimen and determine if adjustments, such as altering the antigen dose or introducing an adjuvant, are necessary. 

Adjuvants are substances that enhance the body's immune response to an antigen. The selection of an appropriate adjuvant is critical, as it influences the magnitude and type of immune response. Various adjuvants are available, each with different mechanisms of action. Alum, for example, is a commonly used adjuvant that stimulates antibody production, while Freund's adjuvant, though highly effective, is no longer widely used due to safety concerns.  

C. Hybridoma Generation (for monoclonal antibodies)

After successful immunization, B cells from the host animal's spleen are isolated and fused with immortal myeloma cells. This somatic cell fusion produces hybridoma cells, which combine the myeloma cells' immortality with the B cells' ability to produce a specific antibody, allowing for continuous production of monoclonal antibodies. 

The hybridomas are then screened for their ability to produce the desired antibody. This involves various assays such as ELISA to identify those cells producing antibodies that specifically bind to the target antigen. Selected hybridomas are expanded and further tested to ensure their specificity and affinity. The hybridomas are cloned, typically using limiting dilution, to ensure that each clone is derived from a single cell, guaranteeing monoclonality, for later harvesting of antibodies for further characterization. 

D. Phage Display or Yeast Display (for recombinant antibodies)

Recombinant antibody technologies, like phage or yeast display, offer a powerful alternative to hybridoma technology for antibody discovery and involve constructing libraries of antibody fragments displayed on the surface of phages or yeast. These libraries are generated from either immunized animals or human B cells, or they can be synthetic, offering a diverse range of antibody sequences. The libraries are screened for binders to the target antigen through a process called biopanning. This involves multiple rounds of binding to the antigen, washing away non-binders, and amplification of the binders, enriching for sequences with high affinity for the antigen. 

Selected antibody fragments are then isolated, sequenced, and further characterized. In some cases, these fragments are converted into full-length antibodies for detailed functional studies. This step ensures that the antibodies not only bind the antigen but are also functionally active in the desired applications, such as neutralizing a toxin or stimulating an immune response. 

E. Antibody Production

For large-scale production, the culture conditions for hybridoma cells or recombinant expression systems (e.g., E. coli, yeast, or mammalian cells) are optimized for oxygen levels, temperature, and medium composition to maximize antibody yield. Antibodies are purified from the culture medium using techniques such as protein A or G affinity chromatography, which exploit the antibody's Fc region for selective binding. Additional purification steps like ion exchange chromatography or size-exclusion chromatography may also be employed to achieve high purity levels. 

Quality control involves rigorous testing of the antibody for specificity, affinity, and absence of contaminants. Validation assays, such as ELISA, Western blot, and immunofluorescence, confirm the antibody's utility in its intended applications. For example, an antibody designed to neutralize a virus might be tested in cell culture to assess its ability to prevent viral infection. 

F. Antibody Characterization

Characterization assays are conducted to determine the antibody's specificity (ability to bind solely to the target antigen) and affinity (strength of binding). High specificity and affinity are crucial for the antibody's effectiveness in research and diagnostic applications. In addition, functional assays, including neutralization tests, flow cytometry, and immunoprecipitation, evaluate the antibody's performance in biological contexts. These assays ensure that the antibody not only recognizes the antigen but also functions as expected in experimental or diagnostic procedures. The stability of the antibody under various storage and handling conditions and its reproducibility across batches are validated. This ensures consistent performance over time and in different settings, a critical aspect for both research and commercial applications. 

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.